Genetic Obesity Disorders Therapeutics
1. Imcivree patent expiration
Treatment: NA
IMCIVREE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(1 year, 9 months from now) | |
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Aug, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-892) | Jun 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2025 |
| Orphan Drug Exclusivity(ODE-336) | Nov 25, 2027 |
| New Patient Population(NPP) | Dec 20, 2027 |
| Orphan Drug Exclusivity(ODE-402) | Jun 16, 2029 |
| Orphan Drug Exclusivity(ODE-508) | Dec 20, 2031 |
| Orphan Drug Exclusivity(ODE-509) | Dec 20, 2031 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 25 November, 2024
Market Authorisation Date: 25 November, 2020
Dosage: SOLUTION
More Information on Dosage
IMCIVREE family patents
